Drug Profile
Research programme: IKK2 inhibitors - GlaxoSmithKline
Latest Information Update: 28 Feb 2011
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Aza compounds; Indoles
- Mechanism of Action I-kappa B kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Feb 2011 No development reported - Preclinical for Rheumatoid arthritis in United Kingdom (PO)
- 20 Aug 2009 Preclinical trials in Rheumatoid arthritis in United Kingdom (PO)